Get insights on the upcoming HOPE 3 phase 3 trial, key endpoints, and investment risks for CAPR. Learn what to watch in ...
Two years after buying CinCor Pharma for $1.3 billion, AstraZeneca has reported that the main asset in the deal, for uncontrolled or treatment-resistant hypertension, has cleared a phase 3 trial.
Cash runway extended through 2026 to fund multiple expected key inflection points PRINCETON, N.J., Sept. 29, 2025 /PRNewswire/ -- Soligenix, Inc.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈